Switching to bedaquiline for treatment of rifampicin-resistant tuberculosis in South Africa: A retrospective cohort analysis.

Authors :: Bouton TC
de Vos M
Ragan EJ
White LF
Van Zyl L
Theron D
Horsburgh CR
Warren RM
Jacobson KR
Source :: PloS one [PLoS One] 2019 Oct 17; Vol. 14 (10), pp. e0223308. Date of Electronic Publication: 2019 Oct 17 (Print Publication: 2019).
Publication Year :: 2019
Abstract: South Africa led the world with guidelines on bedaquiline (BDQ) use as a single drug substitution to manage rifampin resistant tuberculosis regimen toxicity. We examined reasons for giving BDQ in a retrospective cohort: >75% of patients were switched to BDQ for toxicity (ototoxicity or renal dysfunction) rather than drug resistance.<br />Competing Interests: The authors have declared that no competing interests exist.

Full Text Access

Tools